TGFB1 and nonpapillary renal cell carcinoma: Given that oncogenic EVI1 modulates TGF-β signaling [24,25], ccRCC cases with EVI1 over-expression might show differential benefit from immunotherapy, and further studies may warranted to assess the potential benefit of targeting EVI1.